Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
about
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responsesImmunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsAntiviral activity of CYC202 in HIV-1-infected cellsInduction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigensProtection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsPseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challengeMultispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.DNA/MVA Vaccines for HIV/AIDSSafety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersNon-human primate models for AIDS vaccine research.Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within immunodominant Regions Recognized by HIV-infected Indian Patients.DNA vaccines against human immunodeficiency virus type 1 in the past decade.SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccineRecombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesMicroarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challengeCombination vaccines: synergistic simultaneous induction of antibody and T-cell immunity.Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virusNovel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.Therapeutic vaccines against HIV infection.Developments in virus-like particle-based vaccines for HIV.Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodesImmunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
P2860
Q21135240-89064CF3-1229-481D-9A4A-5BE2492DBBFFQ27320923-2D33CEF2-9C41-4A6B-AC04-DA440AFBF9C6Q28292152-F8B13F00-47BA-42AE-8BAC-66B4D0DD9C61Q30339052-681A0E7B-FFDB-4DF4-AF05-EEFE2CACC1CAQ30366666-A141D237-7A65-4E34-BF75-41B83EBB6C52Q30381447-A5449811-9699-4470-978C-09C1FD43864AQ33627613-4E15EC63-E4AA-456E-B1C9-6D44EB68A246Q33737723-58AB24AA-42A5-4A10-B8C3-201F379A6624Q33755041-112308E8-3C8C-4C3D-8BA5-0B12A6CC9E80Q33826983-C6D72A9A-434D-4B9F-A84F-833F09BE2C86Q34059531-131725FF-F622-4A97-92F0-B07C60727D17Q34226966-9BF89246-66BC-4C8B-988B-71FB44A70ACDQ34227778-B4C8D575-0929-401D-839C-F0605CDAD99AQ34348561-3117C2ED-BEF6-4A06-BF08-5739A38660CDQ34492802-BD747EFF-119A-4AAD-97A4-5991560184CCQ34589611-1ABF2ACD-7A2D-4120-A8BE-74DEB1F5245BQ34715769-5B0C908E-C78E-484D-8995-3BCA56053FECQ34772727-561C808B-45BF-40DE-BEB5-61CE20BE6B16Q35183962-3F00F31B-9ABD-43A5-B01E-6626692591C5Q35745831-0B126BF8-9793-4A78-90E8-5B38A941EE39Q35754196-F553516B-1D91-43D2-86B6-5EB58649FD0AQ36129034-7B5F72C5-3B07-4EC6-9B7D-4641C6101529Q36141586-8E7ABFDA-4269-4DB1-9282-85CB02B81602Q36141610-A6CA6F68-AD87-4A58-A7C9-30999ECA6381Q36424574-B7BF5864-5302-4910-B6FB-D029084FC871Q36473859-C2F6CF4D-EDDB-4DC6-8978-A8E9C5756EE4Q36532471-055325D9-B09F-4443-AD21-53C590080DF1Q36538907-7ED67B1B-C282-4D18-8222-89F3D6C97EE9Q36728808-53EA1987-D8FD-4F11-9B81-713B2AEB2576Q37346420-BB8EEE98-1496-49A1-BD67-7BC0D2883EB0Q37355979-5ACE800A-B12C-477D-AD17-1DA8FA9DEFE1Q37656908-CC43FDBE-2BCA-491B-A611-28F10714F4A5Q37682968-119A6DEF-E675-427C-82A5-FF940F245317Q37743813-C7314734-2DC2-43D5-83C4-7F48002C45BFQ37785949-B15274FF-8FB6-443C-8A7B-08F9FDD2EFECQ38013505-109DB2EA-7E20-4BB9-BC86-42255E2B8184Q38081965-A102BCA4-8BA1-4265-9BFE-1D92E2FD6E0DQ38541824-82AEF65A-378C-43EE-9189-8740FE8F6B60Q39756926-6C71D746-211C-420B-B080-B514686A71A1Q40071705-26D58428-4717-46DF-8CFE-028CF408829C
P2860
Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.
@ast
Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.
@en
type
label
Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.
@ast
Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.
@en
prefLabel
Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.
@ast
Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.
@en
P2093
P2860
P1433
P1476
Different patterns of immune r ...... ra (MVA) and DNA/MVA vaccines.
@en
P2093
Francois Villinger
Harold M McClure
Harriet L Robinson
James G Herndon
John D Altman
Linda S Wyatt
Natalia L Kozyr
Patricia L Earl
Rama Rao Amara
Silvija I Staprans
P2860
P304
P356
10.1128/JVI.76.15.7625-7631.2002
P577
2002-08-01T00:00:00Z